Skip to Content
Søg Menu
2.-6. juni 2023

Følg med når vi dækker ASCO 2023 | American Society of Clinical Oncology

Stay tuned

ASCO 2019: Meet the unique needs of older patients with cancer

/ William Dale
ASCO19Cancer Play the Video

Highlights fra ASCO 2023: Nye indsigter i luminal brystkræft

/ Bent Ejlertsen
ASCO23Brystcancer

Significant PFS Benefit for the Nivolumab + Relatlimab Combination for Patients with Unresectable or Metastatic Melanoma

/ BestPractice Nordic
ASCO23Melanom

Adjuvant Osimertinib – New Standard of Care for Patients with Resected EGFR-mutated NSCLC

/ BestPractice Nordic
ASCO23Lungecancer

Få seneste nyt fra dit speciale

Tilmeld dig og bliv opdateret, når der er nyt fra dit speciale

Tilmeld mig
Oluf Dimitri Røe

Can we predict bladder cancer using the HUNT model?

/ Oluf Dimitri Røe
ASCO23Blærecancer Play the Video

NYHED | E-LÆRINGSKURSUS OM IMMUNTERAPI

Immunterapi: Undgå at overse bivirkninger

Tilmeld dig her

Abstracts og artikler fra ASCO 2022

Novel Agent Increases PFS for Patients with endocrine-resistant HR+/HER2- metastatic breast cancer

/ BestPractice Nordic
HER2ASCO22Brystcancer

Ibrutinib added to Standard-of-Care Therapy improves PFS by 50% for Older Patients with Newly Diagnosed Mantle Cell Lymphoma

/ BestPractice Nordic
ASCO22Lymfom

Health-related quality of life is associated with clinical outcomes in patients with advanced renal cell carcinoma

/ BestPractice Nordic
ASCO22Nyrecancer

Nivolumab in combination with relatlimab significantly improved PFS in patients with previously untreated metastatic or unresectable melanoma

/ BestPractice Nordic
ASCO22Hudcancer

Se tidligere dækning af ASCO 2021 og 2020

Potentiel førstelinjebehandling ved avanceret renalcellecarcinom

/ BestPractice Nordic
ASCO21Nyrecancer
Woman with cancer looking at x-ray

Neoadjuvant nivolumab + kemoterapi forbedrer komplet patologisk responsrate og forkorter operationstid uanset stadie af NSCLC

/ BestPractice Nordic
NSCLCLungecancerASCO21
Man at the doctor

Radioligand reducerer risikoen for progression og død for patienter med metastatisk kastrationsresistent prostatacancer

/ BestPractice Nordic
ASCO21Prostatacancer
Self Diagnosis Of Early Breast Cancer

Olaparib kan ændre klinisk praksis i adjuverende behandling af brystcancer

/ BestPractice Nordic
BrystcancerASCO21
Tværsnit af en nyre

KEYNOTE-564 viser lovende resultater for adjuverende behandling med pembrolizumab til højrisiko nyrekræft

/ BestPractice Nordic
ASCO21Nyrecancer
Lung Cancer

Bliver atezolizumab ny standard for adjuverende behandling af patienter med NSCLC?

/ BestPractice Nordic
NSCLCLungecancerASCO21
Mere

Back to top